Literature DB >> 12820409

mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.

Françoise Revillion1, Valérie Pawlowski, Valérie Lhotellier, Marie-Michèle Louchez, Jean-Philippe Peyrat.   

Abstract

BACKGROUND: We recently confirmed, in a series of 365 human breast cancers, that EGFR and c-erbB-2 were associated with estradiol receptors (ER) and/or progesterone receptors (PgR)-negative tumors. Conversely, we demonstrated that c-erbB-3 and c-erbB-4 were positively related to ER and PgR. In the present paper, we simultaneously quantified, for the first time, the mRNA expression of these four receptors in response to estradiol and 4-hydroxy-tamoxifen in the prototypical ER-positive human breast cancer cell line MCF-7.
MATERIALS AND METHODS: The mRNA expression of the type I growth factor receptors was quantified with a one-step real-time RT-PCR assay.
RESULTS: Estradiol down-regulates the mRNA expression of the four receptors. The EGFR decrease is maximal (30% under the control) for 10(-11) M estradiol. For the three other receptors, the decrease (50% under the control) in mRNA expression is maximal with 10(-9) M. These effects are completely abolished by 4-OH tamoxifen at 10(-6) M.
CONCLUSION: In MCF-7 cells, we demonstrate that c-erbB-4 is down-regulated by estradiol and up-regulated by 4-OH tamoxifen, and confirm that the three other receptors followed the same pattern of expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820409

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.

Authors:  Tissa T Manavalan; Yun Teng; Savitri N Appana; Susmita Datta; Theodore S Kalbfleisch; Yong Li; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2011-09-10       Impact factor: 8.679

2.  Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.

Authors:  Xihong Zhang; Michael R Diaz; Douglas Yee
Journal:  Breast Cancer Res Treat       Date:  2013-05-18       Impact factor: 4.872

Review 3.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

Review 4.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

5.  Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Authors:  Thomas Frogne; Rikke V Benjaminsen; Katrine Sonne-Hansen; Boe S Sorensen; Ebba Nexo; Anne-Vibeke Laenkholm; Louise M Rasmussen; David J Riese; Patricia de Cremoux; Jan Stenvang; Anne E Lykkesfeldt
Journal:  Breast Cancer Res Treat       Date:  2008-04-14       Impact factor: 4.872

6.  Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Authors:  Iain R Hutcheson; Lindy Goddard; Denise Barrow; Richard A McClelland; Hayley E Francies; Janice M Knowlden; Robert I Nicholson; Julia M W Gee
Journal:  Breast Cancer Res       Date:  2011-03-11       Impact factor: 6.466

7.  Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4.

Authors:  Robert L Sutherland
Journal:  Breast Cancer Res       Date:  2011-05-20       Impact factor: 6.466

8.  Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.

Authors:  Marianne Hauglid Flågeng; Stian Knappskog; Ben P Haynes; Per Eystein Lønning; Gunnar Mellgren
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

9.  ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.

Authors:  S R Krig; J K Miller; S Frietze; L A Beckett; R M Neve; P J Farnham; P I Yaswen; C A Sweeney
Journal:  Oncogene       Date:  2010-07-26       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.